Explore AC-262 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
AC-262 is a non-steroidal selective androgen receptor modulator (SARM) characterized only in preclinical work, with no human trials. It is a small molecule, not a peptide, and is banned in sport by WADA, so the certificate of analysis (COA) is about chemical purity and accurate dosing.
AC-262 binds the androgen receptor as a partial agonist with greater agonist activity in muscle and CNS tissues than in prostate, on the basis of the Acadia preclinical characterisation.[1] The CNS-tissue-selectivity premise — based on tissue-distribution and in-vivo behavioural assays in rodents — was the original rationale for considering it in indications where central androgen-receptor activity might be relevant (cognition, mood, libido) rather than for the muscle-building applications consumers now use it for. No human data exist to confirm whether the rodent CNS-selectivity translates.
The Acadia pre-clinical characterisation describes AC-262 as orally active with modest anabolic activity in rat levator-ani muscle and reduced prostate-trophic activity relative to testosterone, plus measurable effects in rodent behavioural assays sensitive to central AR signalling.[1] No registered ClinicalTrials.gov trial of AC-262 has been conducted in humans for any indication.[2] The published human safety and efficacy literature on AC-262 is essentially zero; consumer use sits entirely outside the clinical-trial framework and outside the published SARM-class human-safety evidence base (which itself is sparse).[4]
Not FDA-approved. No registered clinical trial. Pre-clinical (rodent) data only. WADA-prohibited at all times. Research-grade material only.
AC-262 has a reported half-life of ~12 hours (estimated). The pharmacokinetic reference models an interval of once daily (oral); this is not a measured community cadence or a dosing recommendation. A moderate half-life means once-daily dosing keeps a meaningful amount in your system between doses, with modest buildup over the first day or two. Pharmacokinetic source: No human PK data; pre-clinical SARM (AC-262,356; Acadia Pharmaceuticals). It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough AC-262 calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.